Biota acquires antibacterial projects from two firms
13 November 2009
Ian Haydock
Please Login to read the full article.
13 November 2009
Ian Haydock
ian.haydock@informa.com
Biota Holdings has acquired early stage antibacterial programmes from the UK firm Prolysis and MaxThera of the US, in an effort to extend its research interests beyond antivirals and into the wider anti-infective area.
The Australian firm will pay £6.4 million in newly issued shares...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Rib-X inks potentially lucrative deal with Sanofi for new class of antibiotics
- Optimer Inks $30 million co-promotion deal for Dificid with Cubist
- Astellas breaks off Vibativ partnership withTheravance
- Rib-X Pharma files for IPO to finance antibiotics providing superior coverage
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
